![Philip Ashton-Rickardt](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philip Ashton-Rickardt
Chief Tech/Sci/R&D Officer at
SIGILON THERAPEUTICS, INC.
Profile
Philip Ashton-Rickardt was the founder of Smith Therapeutics, Inc. (founded in 2017), where he held the titles of President, CEO, Secretary & Director until 2019.
He is currently the Chief Scientific Officer at Sigilon Therapeutics, Inc. (since 2021).
Previously, he worked as the Chairman of Immunology at Imperial College London, Senior Vice President of Immunology at AZTherapies, Inc. (2019-2021), and Associate Professor at The University of Chicago (1995-2006).
Dr. Ashton-Rickardt obtained his doctorate degree from The University of Edinburgh and his undergraduate degree from King's College London.
Philip Ashton-Rickardt active positions
| Companies | Position | Start |
|---|---|---|
| SIGILON THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 14/06/2021 |
Former positions of Philip Ashton-Rickardt
| Companies | Position | End |
|---|---|---|
AZTherapies, Inc.
 AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs for Alzheimer's disease | Corporate Officer/Principal | 01/06/2021 |
Smith Therapeutics, Inc.
 Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Founder | 31/10/2019 |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01/06/2006 |
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Training of Philip Ashton-Rickardt
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
95
1st degree connections
7
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
AZTherapies, Inc.
AZTherapies, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes drugs for Alzheimer's disease | Health Technology |
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Edinburgh
 The University of Edinburgh Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The University of Chicago
The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
King's College London
 King's College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Sigilon Therapeutics, Inc.
 Sigilon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutics and functional cures for patients with chronic diseases | Health Technology |
Smith Therapeutics, Inc.
Smith Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products | Health Technology |
- Stock Market
- Insiders
- Philip Ashton-Rickardt
